EcoDrugPlus

Endothelin-1 Receptor

Ensembl ID : ENSLCAG00010022576
Gene Symbol: LOC108873728
4 Cross references
196 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSLCAG00010025323
Gene Symbol: LOC108884998
4 Cross references
229 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSLCAG00010020755
Gene Symbol: EPHB4B
1 Cross references
168 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSLCAG00010006879
Gene Symbol: EGFR
4 Cross references
214 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSLCAG00010001759
Gene Symbol: EGFRA
4 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSLCAG00010019713
Gene Symbol: EPHX2
1 Cross references
203 Possible Orthologues:

Equilibrative Nucleoside Transporter 1

Ensembl ID : ENSLCAG00010011763
Gene Symbol: LOC108880345
4 Cross references
208 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSLCAG00010004938
Gene Symbol: LOC108890417
4 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSLCAG00010022392
Gene Symbol: ERBB3B
4 Cross references
206 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSLCAG00010020008
Gene Symbol: ERBB4
1 Cross references
47 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSLCAG00010006104
Gene Symbol: ESR1
1 Cross references
215 Possible Orthologues:

Estrogen Receptor 2a

Ensembl ID : ENSLCAG00010024385
Gene Symbol: ESR2A
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).